Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation

Metabolomics

Volumn 6, Issue 2, 2010, Pages 229-237

  Alcarraz Vizán, Gema ^a   Boren, Joan ^a,c   Lee, Wai Nang Paul ^b   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Butyrate; Cell differentiation; Histone deacetylase; Medium chain fatty acids; Metabolism; Trichostatin A

Indexed keywords

EID: 77952091125     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-009-0192-0     Document Type: Article

References (37)

1. Bergmeyer, H. U. (Ed.). (1985). Methods of enzymatic analysis. Weinheim: Verlag Dhemie.
2. Boren, J., Lee, W.-N. P., Bassilian, S., et al. (2003). The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. Journal of Biological Chemistry, 278, 28395-28402.
3. Csordas, A. (1990). On the biological role of histone acetylation. Biochemical Journal, 265, 23-38.
4. Dangond, F., & Gullans, S. R. (1998). Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochemical and Biophysical Research Communications, 247, 833-837.
5. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochemical Journal, 370, 737-749.
6. Egler, V., Korur, S., Failly, M., et al. (2008). Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clinical Cancer Research, 14, 3132-3140.
7. Heerdt, B. G., Houston, M. A., & Augenlicht, L. H. (1994). Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Research, 54, 3288-3293.
8. Jethva, R., Bennett, M. J., & Vockley, J. (2008). Short-chain acyl-coenzyme A dehydrogenase deficiency. Molecular Genetics and Metabolism, 95, 195-200.
9. 13C] glucose in rats. Journal of Biological Chemistry, 264, 12994-13004.
10. Kelly, W. K., O'Connor, O. A., & Marks, P. A. (2002). Histone deacetylase inhibitors: From target to clinical trials. Expert Opinion on Investigational Drugs, 11, 1695-1713.
11. Kieweg, V., Krautle, F. G., Nandy, A., et al. (1997). Biochemical characterization of purified, human recombinant Lys304→ Glu medium-chain acyl-CoA dehydrogenase containing the common disease-causing mutation and comparison with the normal enzyme. European Journal of Biochemistry, 246, 548-556.
12. Kouraklis, G., & Theocharis, S. (2006). Histone deacetylase inhibitors: A novel target of anticancer therapy (review). Oncology Reports, 15, 489-494.
13. Kwon, H. S., & Harris, R. A. (2004). Mechanisms responsible for regulation of pyruvate dehydrogenase kinase 4 gene expression. Advances in Enzyme Regulation, 44, 109-121.
14. Kwon, H. S., Huang, B., Ho Jeoung, N., Wu, P., Steussy, C. N., & Harris, R. A. (2006). Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. Biochimica et Biophysica Acta, 1759, 141-151.
15. Lee, W. N. (1996). Stable isotopes and mass isotopomer study of fatty acid and cholesterol synthesis. A review of the MIDA approach. Advances in Experimental Medicine and Biology, 399, 95-114.
16. 2] glucose. American Journal of Physiology, 274, E843-E851.
17. Litvak, D. A., Evers, B. M., Hwang, K. O., Hellmich, M. R., Ko, T. C., & Townsend, C. M., Jr. (1998). Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21Waf1/Cip1 and p27Kip1. Surgery, 124, 161-169. discussion 169-170.
18. Mariadason, J. M. (2008). HDACs and HDAC inhibitors in colon cancer. Epigenetics, 3, 28-37.
19. Marks, P. A., & Xu, W. S. (2009). Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry, 107(4), 600-608.
20. Martin, M., Kettmann, R., & Dequiedt, F. (2007). Class IIa histone deacetylases: Regulating the regulators. Oncogene, 26, 5450-5467.
21. Matito, C., Mastorakou, F., Centelles, J. J., Torres, J. L., & Cascante, M. (2003). Antiproliferative effect of antioxidant polyphenols from grape in murine Hepa-1c1c7. European Journal of Nutrition, 42, 43-49.
22. Mazurek, S., & Eigenbrodt, E. (2003). The tumor metabolome. Anticancer Research, 23, 1149-1154.
23. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
24. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., & Richon, V. M. (2001). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Research, 61, 8492-8497.
25. Oki, Y., & Issa, J. P. (2006). Review: Recent clinical trials in epigenetic therapy. Reviews on Recent Clinical Trials, 1, 169-182.
26. Perrine, S. P., Hermine, O., Small, T., et al. (2007). A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood, 109, 2571-2578.
27. Ramos-Montoya, A., Lee, W. N., Bassilian, S., et al. (2006). Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. International Journal of Cancer, 119, 2733-2741.
28. Roediger, W. E. (1982). Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology, 83, 424-429.
29. Rossignol, R., Gilkerson, R., Aggeler, R., Yamagata, K., Remington, S. J., & Capaldi, R. A. (2004). Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Research, 64, 985-993.
30. 3 and p21 expression. Gut, 46, 507-514.
31. Smith, K. T., & Workman, J. L. (2009). Histone deacetylase inhibitors: Anticancer compounds. International Journal of Biochemistry and Cell Biology, 41(1), 21-25.
32. Villar-Garea, A., & Esteller, M. (2004). Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. International Journal of Cancer, 112, 171-178.
33. Vizán, P., Mazurek, S., & Cascante, M. (2008). Robust metabolic adaptation underlying tumor progression. Metabolomics, 4, 1-12.
34. Waldecker, M., Kautenburger, T., Daumann, H., Busch, C., & Schrenk, D. (2008). Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. Journal of Nutritional Biochemistry, 19, 587-593.
35. Wilson, A. J., Byun, D. S., Popova, N., et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry, 281, 13548-13558.
36. Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009). HDAC family: What are the cancer relevant targets? Cancer Letters, 277, 8-21.
37. Woo, H. J., Lee, S. J., Choi, B. T., Park, Y. M., & Choi, Y. H. (2007). Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Experimental and Molecular Pathology, 82, 77-84.